Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Multi-drug resistant (MDR) Gram-negative pathogens pose a significant global health threat.
• Key pathogens include Enterobacteriaceae, Acinetobacter spp., and Pseudomonas aeruginosa, with limited treatment options.
• Aminoglycosides and polymyxins remain vital, but resistance is increasing.

Purpose of the Study:

• To review plazomicin's (ACHN-490) biochemistry, pharmacokinetics, pharmacodynamics, and in-vitro activity.
• To discuss ongoing clinical trial progress for plazomicin.
• To evaluate plazomicin's potential therapeutic role against MDR Gram-negative infections.

Main Methods:

• Literature review of available data on plazomicin.
• Analysis of in-vitro susceptibility data against MDR Gram-negative bacteria.
• Examination of pharmacokinetic/pharmacodynamic (PK/PD) properties.
• Summary of clinical trial outcomes and safety data.

Main Results:

• Plazomicin exhibits unique structural modifications conferring activity against many MDR Gram-negative organisms.
• Recently approved by the FDA for complicated urinary tract infections caused by MDR Enterobacteriaceae.
• Demonstrates potent in-vitro activity against key Gram-negative pathogens.

Conclusions:

• Plazomicin represents a promising therapeutic option for MDR Gram-negative infections.
• Optimal use requires understanding its PK/PD and clinical efficacy.
• Further evaluation is crucial in the context of rising antimicrobial resistance.